II. Indications
- Cerebral Vasospasm following Subarachnoid Hemorrhage (FDA Approved)
- Blood Pressure Control after Cerebrovascular Accident
III. Contraindications
- Liver Failure
- Hypotension
IV. Mechanism
- Second Generation Dihydropyridine Calcium Channel Blocker
- Inhibits vascular Smooth Muscle contractility
V. Pharmacokinetics
- Crosses the blood brain barrier (lipophilic)
VI. Safety
- Unknown safety in pregnancy
- Present in Breast Milk
VII. Dosing: Adult
- Started within 96 hours of event and continued for 21 days
- Standard Dose (including in impaired Renal Function)
- Nimodipine 60 mg orally or via Nasogastric Tube every 4 hours
- Reduced Dose (Cirrhosis)
- Nimodipine 30 mg orally or via Nasogastric Tube every 4 hours
VIII. Precautions
- Do NOT use Parenterally due to cardiovascular event risk (may be lethal)
- Monitor Blood Pressure
IX. Adverse Effects
X. Resources
XI. References
- Spencer and LoVecchio (2021) Crit Dec Emerg Med 35(7): 32
- Liu (2011) CNS Neurol Disord Drug Targets 10(7):834-44 +PMID: 21999736 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
| nimodipine (on 12/20/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| NIMODIPINE 30 MG CAPSULE | Generic | $0.99 each |